ERIBULIN Drug Patent Profile
✉ Email this page to a colleague
When do Eribulin patents expire, and when can generic versions of Eribulin launch?
Eribulin is a drug marketed by Baxter Hlthcare Corp, Chia Tai Tianqing, Dr Reddys, Gland, Glenmark Pharms, Jiangxi Kvvit Pharm, Long Grove Pharms, Sandoz, and Xgen Pharms. and is included in nine NDAs.
The generic ingredient in ERIBULIN is eribulin mesylate. Sixteen suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eribulin
A generic version of ERIBULIN was approved as eribulin mesylate by GLAND on April 5th, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ERIBULIN?
- What are the global sales for ERIBULIN?
- What is Average Wholesale Price for ERIBULIN?
Summary for ERIBULIN
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| DailyMed Link: | ERIBULIN at DailyMed |
US Patents and Regulatory Information for ERIBULIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 217250-001 | Oct 1, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Long Grove Pharms | ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 214850-001 | Jul 18, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Gland | ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 218047-001 | Apr 5, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sandoz | ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 214310-001 | Jun 9, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Chia Tai Tianqing | ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 218743-001 | Mar 4, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
